Theravance Biopharma TBPH Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's business segments — net income loss?
- Theravance Biopharma (TBPH) reported business segments — net income loss of -$4.93M in Q1 2026.
- How has Theravance Biopharma's business segments — net income loss changed year-over-year?
- Theravance Biopharma's business segments — net income loss increased by 63.7% year-over-year, from -$13.58M to -$4.93M.
- What is the long-term trend for Theravance Biopharma's business segments — net income loss?
- Over 2 years (2023 to 2025), Theravance Biopharma's business segments — net income loss has grown at a 38.5% compound annual growth rate (CAGR), from -$55.19M to $105.9M.
- What does business segments — net income loss mean?
- This represents the final bottom-line profit or loss for the segment after accounting for all operating expenses, non-operating items, and tax impacts. It is the ultimate measure of the segment's financial performance and its contribution to the overall profitability of the organization.